Author

C. S. Mitsiades

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

J. A. Roth· 2 shared R. de Matos Simoes· 2 shared R. Shirasaki· 2 shared A. Carrasco· 1 shared A. Melnick· 1 shared A. Näätänen· 1 shared A. P. Wiita· 1 shared A. Vilas-Zornoza· 1 shared

Activity by Year

2017-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

J. A. Roth

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Highly specific intracellular ubiquitination of a small molecule

W. Li, E. M. Garcia-Rivera, D. C. Mitchell, J. M. Chick, M. Maetani, J. M. Knapp, G. M. Matthews, R. Shirasaki, R. de Matos Simoes, V. Viswanathan, J. L. Pulice, M. G. Rees, J. A. Roth, S. P. Gygi, C. S. Mitsiades, , J. M. L. Ostrem

The paper identifies a small molecule, BRD1732, that is ubiquitinated in cells, leading to proteasome inhibition through accumulation of ubiquitin chains.

bioRxiv · Jan 26, 2024Biochemistry

Single-cell functional genomics of natural killer cell evasion in blood cancers

O. Dufva, S. Gandolfi, J. Huuhtanen, O. Dashevsky, K. Saeed, J. Klievink, P. Nygren, J. Bouhlal, J. Lahtela, A. Näätänen, B. Ghimire, T. Hannunen, P. Ellonen, H. Duan, J. Theodoropoulos, , S. Mustjoki

The paper uses single-cell and genome-scale functional genomics to study how blood cancer cells evade NK cells, identifying key genes and pathways involved in resistance and sensitivity.

bioRxiv · Aug 22, 2022 · PreprintImmunology

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

R. Ordonez, M. Kulis, N. Russinol, V. Chapaprieta, R. Beekman, C. Meydan, M. Duran-Ferrer, N. Verdaguer-Dot, G. Clot, R. Vilarrasa-Blasi, L. Garate, E. Miranda, A. Carrasco, T. Ezponda, A. Vilas-Zornoza, , J. I. Martin-Subero

The paper identifies aberrant chromatin activation as a common mechanism driving the malignant phenotype in multiple myeloma.

bioRxiv · Aug 20, 2019Cancer Biology

Repurposing Tofacitinib As An Anti-Myeloma Therapeutic To Reverse Growth-Promoting Effects Of The Bone Marrow Microenvironment

C. Lam, M. Murnane, H. Liu, G. A. Smith, S. Wong, J. Taunton, J. O. Liu, C. S. Mitsiades, B. C. Hann, B. T. Aftab, A. P. Wiita

This paper validates tofacitinib as an effective anti-myeloma therapy by reversing bone marrow microenvironment-driven growth signals in vitro and in vivo.

bioRxiv · May 28, 2017Cancer Biology